Project Grant R01HL179534
Award Date
6/20/25
Completion Date
4/30/29
Dollars Obligated
$491K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $502,294 to Georgia TECH Research Corp to conduct research on engineered biomaterials for promoting lymphatic regeneration in lymphedema. The project aims to integrate advanced biomaterials and targeted delivery of lipid nanoparticles into current lymphedema surgical procedures to augment lymphangiogenesis and enhance lymphedema treatment. Key activities...
This $144,362 Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a research project focused on investigating the effectiveness and mechanisms of lymphaticovenous anastomoses (LVA) for treating lymphedema. The research integrates computational modeling with clinical LVA insights to gain a deeper understanding of lymphatic flow dynamics and adaptations in response to this surgical intervention. The project, led by...
The National Cancer Institute (NCI) awarded a $556,684 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Palo Alto Veterans Institute for Research (PAVIR) to develop a bioengineered therapeutic device for the prevention of lymphedema. The objective is to optimize the structural and mechanical properties of a collagen conduit implant to promote lymphatic regeneration and normalize lymph flow, thereby preventing the onset of lymphedema in at-risk cancer patients. As a...
The National Cancer Institute awarded a 5-year, $516,114 Project Grant (CFDA 93.395 Cancer Treatment Research) to The University of Texas MD Anderson Cancer Center to investigate the impact of immediate lymphatic reconstruction (ILR) surgery on preventing lymphedema in patients with inflammatory breast cancer. The key products or services to be delivered under this grant include: Conducting near-infrared fluorescence lymphatic imaging (NIRF-LI) to longitudinally assess changes in lymphatic...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research to investigate the genetic and environmental factors contributing to the development of complex lymphatic anomalies (CLAs), a group of rare and debilitating vascular diseases. The $508,436 award to The University of Texas Southwestern Medical Center will test the hypothesis that CLAs require both a genetic mutation and a permissive lymphangiogenic...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
This National Science Foundation (NSF) Engineering Program (CFDA 47.041) award of $470,955 to Cornell University aims to develop a microfluidic cell culture platform to study breast cancer-associated secondary lymphedema. The 5-year project seeks to comprehend the regulation of lymphatic structure and function in breast cancer, and discover new treatment approaches for the over 150 million lymphedema patients worldwide. The research involves creating engineered lymphatic vessel models to analyze...
This $704,795 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Baylor College of Medicine supports the development of a novel cell-based immunomodulation therapy to suppress lung inflammation and promote repair in Acute Respiratory Distress Syndrome (ARDS). The project aims to engineer retinal pigment epithelial (RPE) cells to produce anti-inflammatory cytokines IL-1RA and IL-10 and encapsulate them in alginate-based...
Larix Bioscience LLC received a $245,728 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports the company's research and development of novel therapies for improving lymphatic dysfunction, a complication commonly associated with obesity and diabetes. Specifically, the grant funds the generation and preclinical evaluation of albumin and Fc fusion protein therapeutics targeting adrenomedullin...
This federal Project Grant award, totaling $1,585,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant is titled "Targeting Lymphatic Chemokine Signaling to Promote Lymphangiogenesis for the Treatment of Lymphedema" and was awarded to Temple University-Of The Commonwealth System Of Higher Education on March 1, 2025, with a planned completion date of February 28, 2029. The grant aims to...